文献速递系统性红斑狼疮

抗CD40单克隆抗体治疗狼疮性肾炎患者的肾脏活检特征与结局

Outcome of Patients With Lupus Nephritis Treated With an Anti-CD40 Monoclonal Antibody According to Kidney Biopsy Features.
PubMed 文献 · Arthritis Rheumatol · 2025-01-28

一项2期试验的事后分析,对101例III或IV型活动性狼疮性肾炎患者的肾活检进行中央评分,评估BI 655064(抗CD40单克隆抗体)疗效是否受肾小球单核细胞影响。结果显示,肾小球单核细胞存在时,高剂量BI 655064(180或240 mg)与尿蛋白/肌酐比值和完全肾脏缓解的改善相关(OR 3.66和4.58),eGFR有改善趋势(52周P=0.08)。

要点

  • 肾小球单核细胞存在时,高剂量BI 655064与尿蛋白/肌酐比值改善相关(OR 3.66)。
  • 肾小球单核细胞存在时,高剂量BI 655064与完全肾脏缓解率提高相关(OR 4.58)。
  • 肾小球单核细胞存在时,高剂量BI 655064组eGFR有改善趋势(52周P=0.08)。

核心结论

  • 在伴有肾小球单核细胞的狼疮性肾炎肾活检样本中,高剂量BI 655064治疗在52周时改善蛋白尿,并较无肾小球单核细胞的样本获得更高的完全肾脏缓解率。
  • 组织学特征可能指导狼疮性肾炎个体患者的治疗选择(作者认为)。

研究设计与样本

  • 2期试验的事后分析,纳入101例III或IV型活动性狼疮性肾炎患者的肾活检,进行中央评分。
  • 患者按混合模型重复测量预测的转归优于或劣于队列平均分为「较好」和「较差」两组。
  • 采用校正潜在混杂因素的逻辑回归模型,评估不同治疗剂量与结局的关联,并按肾小球单核细胞有无分层。

主要发现

  • 肾小球单核细胞存在时,较高剂量BI 655064(180或240 mg)与尿蛋白/肌酐比值改善相关(OR 3.66,95%CI 1.09-12.3,P=0.04)。
  • 肾小球单核细胞存在时,较高剂量BI 655064(180或240 mg)与完全肾脏缓解改善相关(OR 4.58,95%CI 1.24-16.9,P=0.02)。
  • 肾小球单核细胞存在时,较高剂量BI 655064组eGFR有改善趋势(52周P=0.08)。

关键数值与推荐

  • 肾小球单核细胞存在时,高剂量BI 655064(180或240 mg)与尿蛋白/肌酐比值改善的OR为3.66(95%CI 1.09-12.3,P=0.04)。
  • 肾小球单核细胞存在时,高剂量BI 655064(180或240 mg)与完全肾脏缓解的OR为4.58(95%CI 1.24-16.9,P=0.02)。
  • 肾小球单核细胞存在时,高剂量BI 655064组52周eGFR改善趋势的P=0.08。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A phase 2 trial tested different doses of the anti-CD40 monoclonal antibody BI 655064 as an add-on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo. We investigated whether the treatment effect of BI 655064 on kidney outcomes may be modified by the presence of glomerular monocytes, a target for this drug with a well-known role in LN pathogenesis. METHODS: One hundred one renal biopsies of patients with LN enrolled in the BI 655064 trial were scored centrally. The estimated glomerular filtration rate (eGFR), spot urine protein/urine creatinine ratio (UP/UC), and complete renal response (CRR) were evaluated over 52 weeks. Patients were divided according to a "better" or "worse" performance than the average of all patients in the cohort, predicted by a mixed model for repeated measurements. Logistic regression models adjusted for potential confounders were used to assess the association between different treatment doses and outcomes according to the presence or absence of monocytes. RESULTS: A higher BI 655064 dose (180 or 240 mg) was associated with better outcomes of UP/UC and CRR when glomerular monocytes were present in kidney biopsy samples (odds ratio [OR] 3.66 [95% confidence interval (CI) 1.09-12.3], P = 0.04; OR 4.58 [95% CI 1.24-16.9], P = 0.02). A trend toward improved eGFR was also observed in these patients (at 52 weeks, P = 0.08). CONCLUSION: In LN kidney biopsy samples with glomerular monocytes, high-dose BI 655064 treatment improved proteinuria at 52 weeks and resulted in a higher CRR compared to biopsy samples without glomerular monocytes. Histologic features may guide the choice of treatment for individual patients with LN.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Uzzo M, Schumacher H, Steffgen J, et al. Outcome of Patients With Lupus Nephritis Treated With an Anti-CD40 Monoclonal Antibody According to Kidney Biopsy Features. Arthritis Rheumatol. 2025. PMID: 39648337. doi:10.1002/art.43076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。